The restless leg syndrome (RLS) market is anticipated to exhibit a moderate CAGR of 6.0% during the forecast period. The exact cause of RLS is yet not know it is expected to occur due to chronic diseases such as diabetes, Parkinson’s disease, kidney failure, or renal diseases. As per the Health and Safety Executive (HSE), in Great Britain, during the period (2018-2019), the total number of cases associated with work-related stress, depression, or anxiety was around 600,000, a prevalence rate of 1,800 per 100,000 workers. The number of new cases was 246,000, an incidence rate of 740 per 100,000 workers. The rising work-related stress that imparts due pressure on the nervous system is expected to be a major cause of RLS. Therefore, the high prevalence of work stress-related RLS is anticipated to create the demand for treatment of RLS using different drug devices, and therapy which in turn will drive the market growth.
A full report of Restless Legs Syndrome Market is available at: https://www.omrglobal.com/industry-reports/restless-legs-syndrome-market
The continuous contributions from the key players operating in the market are again making huge contributions to the global RLS Market. Pfizer, Inc., GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Glenmark Pharmaceuticals Ltd., and so on are some of the key players contributing to the growth of the global RLS market. Some of the main strategies adopted by the players to cope with the competitive market and improve their role in the global RLS market are new product launches & innovations, alliances, agreements, and acquisitions.
For instance, in July 2019, Serina Therapeutics started developing a rotigotine formally known as SER-214, a dopamine agonist for the treatment of Restless Legs Syndrome (RLS). If the trial successful, it will significantly change the treatment landscape for patients as well as physicians across the globe. Additionally, in August 2019, Jazz Pharmaceuticals Inc. had acquired Cavion, Inc. This deal adds global rights for the future treatment of critical tremors to CX-8998, a T-type calcium channel modulator. Also, this acquisition represents an attractive opportunity for the company to broaden its sleep and neuroscience pipeline with expansion into movement disorders demonstrated proof-of-concept in phase 2 randomized, placebo-controlled trials.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/restless-legs-syndrome-market
Key Market Trends Covered in the Report
- Psychiatric reasons have been the major propellent factor for the market for ages.
- North America is anticipated to hold a major share global RLS market.
- Mergers & Acquisition, Product Launches, and partnerships: key strategies of players to thrive in the market.
Global Restless Leg Syndrome Market – Segmentation
By Treatment
- Medication
- Therapy
- Devices
By End-User
- Hospitals
- Homecare
- Others
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
